Logo image of CRMD

CORMEDIX INC (CRMD) Stock Overview

USA - NASDAQ:CRMD - US21900C3088 - Common Stock

11.31 USD
+0.17 (+1.53%)
Last: 10/29/2025, 8:21:39 PM
11.34 USD
+0.03 (+0.27%)
After Hours: 10/29/2025, 8:21:39 PM

CRMD Key Statistics, Chart & Performance

Key Statistics
Market Cap844.29M
Revenue(TTM)121.48M
Net Income(TTM)51.16M
Shares74.65M
Float69.01M
52 Week High17.43
52 Week Low5.6
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.75
PE15.08
Fwd PE4.46
Earnings (Next)11-06 2025-11-06/bmo
IPO2010-03-25
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


CRMD short term performance overview.The bars show the price performance of CRMD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15 20

CRMD long term performance overview.The bars show the price performance of CRMD in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200 250

The current stock price of CRMD is 11.31 USD. In the past month the price increased by 2.35%. In the past year, price increased by 13.21%.

CORMEDIX INC / CRMD Daily stock chart

CRMD Latest News, Press Relases and Analysis

CRMD Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 50.37 769.97B
JNJ JOHNSON & JOHNSON 17.98 449.40B
AZN ASTRAZENECA PLC-SPONS ADR 18.52 254.96B
NVS NOVARTIS AG-SPONSORED ADR 13.47 235.79B
NVO NOVO-NORDISK A/S-SPONS ADR 13.21 228.26B
MRK MERCK & CO. INC. 11.24 216.26B
PFE PFIZER INC 7.17 138.10B
SNY SANOFI-ADR 11.47 123.51B
GSK GSK PLC-SPON ADR 10.3 92.38B
BMY BRISTOL-MYERS SQUIBB CO 6.33 86.71B
ZTS ZOETIS INC 23.14 63.79B
TAK TAKEDA PHARMACEUTIC-SP ADR 49.18 43.49B

About CRMD

Company Profile

CRMD logo image CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 64 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

Company Info

CORMEDIX INC

300 Connell Drive, Suite 4200

Berkeley Heights NEW JERSEY 07922 US

CEO: Khoso Baluch

Employees: 64

CRMD Company Website

CRMD Investor Relations

Phone: 19085179500

CORMEDIX INC / CRMD FAQ

What does CRMD do?

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 64 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.


What is the stock price of CORMEDIX INC today?

The current stock price of CRMD is 11.31 USD. The price increased by 1.53% in the last trading session.


What is the dividend status of CORMEDIX INC?

CRMD does not pay a dividend.


How is the ChartMill rating for CORMEDIX INC?

CRMD has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


On which exchange is CRMD stock listed?

CRMD stock is listed on the Nasdaq exchange.


Is CORMEDIX INC (CRMD) expected to grow?

The Revenue of CORMEDIX INC (CRMD) is expected to grow by 596.96% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the market capitalization of CRMD stock?

CORMEDIX INC (CRMD) has a market capitalization of 844.29M USD. This makes CRMD a Small Cap stock.


CRMD Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to CRMD. When comparing the yearly performance of all stocks, CRMD turns out to be only a medium performer in the overall market: it outperformed 52.94% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CRMD Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to CRMD. CRMD has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CRMD Financial Highlights

Over the last trailing twelve months CRMD reported a non-GAAP Earnings per Share(EPS) of 0.75. The EPS increased by 180.65% compared to the year before.


Industry RankSector Rank
PM (TTM) 42.11%
ROA 20.25%
ROE 23.19%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%212%
Sales Q2Q%4829.39%
EPS 1Y (TTM)180.65%
Revenue 1Y (TTM)14970.65%

CRMD Forecast & Estimates

13 analysts have analysed CRMD and the average price target is 20.91 USD. This implies a price increase of 84.88% is expected in the next year compared to the current price of 11.31.

For the next year, analysts expect an EPS growth of 733.33% and a revenue growth 596.96% for CRMD


Analysts
Analysts81.54
Price Target20.91 (84.88%)
EPS Next Y733.33%
Revenue Next Year596.96%

CRMD Ownership

Ownership
Inst Owners46.71%
Ins Owners7.55%
Short Float %23.45%
Short Ratio4.77